CSL Ltd Annual Report 2019

A healthier more productive society Protecting global health and the wellbeing of individuals, families, businesses and communities from life-threatening and/or complications resulting from influenza. Saving and/or improving the quality of life of hundreds and thousands of people with rare and serious diseases. Sustainable financial growth Delivering consistent, profitable and responsible growth for our investors, which fuels innovation and development of our product pipeline. Social and economic opportunity Enabling hundreds of thousands of people to benefit from opportunity created by growing along with us, including employees, suppliers, plasma donors and research partners. Unmet need Opportunities to improve and protect the quality of life of patients in therapy areas we treat. Our people 25,000+ people with diverse skills that are driven by our purpose and values. Natural resources Includes: plasma donations for rare and serious diseases; influenza virus strains for product manufacture; and environmental inputs such as water and energy. Financial resources Cash, equity and debt for future growth. Physical assets Plasma centres to collect rawmaterial, manufacturing facilities for our products, warehouses, offices for our people and laboratories for our scientists. Collaborators and business partners Accessing and sharing intellectual know to develop and innovate our products. What we draw on Value we create 14 How we create value CSL Limited Annual Report 2019 12 CSL Strategy